Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Liu, Yu Ping ^a   Suksanpaisan, Lukkana ^a   Steele, Michael B ^a   Russell, Stephen J ^a   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; TUMOR PROTEIN;

ARTICLE; EXPERIMENTAL NEOPLASM; HUMAN; MACROPHAGE; METABOLISM; METHODOLOGY; ONCOLYTIC VIROTHERAPY; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; VIROLOGY; PROCEDURES;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; HUMANS; MACROPHAGES; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; TUMOR MICROENVIRONMENT;

EID: 84881414523     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02375     Document Type: Article

References (52)

1. Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nature biotechnology 30, 658-670 (2012).
2. Eager, R. M. & Nemunaitis, J. Clinical development directions in oncolytic viral therapy. Cancer gene therapy 18, 305-317 (2011).
3. Wollmann, G., Ozduman, K. & van den Pol, A. N. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 18, 69-81 (2012).
4. Thorne, S. H., Hermiston, T. & Kirn, D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 32, 537-548 (2005). (Pubitemid 41772681)
5. Kelly, E. J. & Russell, S. J. MicroRNAs and the regulation of vector tropism. Molecular therapy: the journal of the American Society of Gene Therapy 17, 409-416 (2009).
6. Touchefeu, Y., Franken, P. & Harrington, K. J. Radiovirotherapy: principles and prospects in oncology. Curr Pharm Des 18, 3313-3320 (2012).
7. Wennier, S. T., Liu, J. & McFadden, G. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. Curr Pharm Biotechnol 13, 1817-1833 (2012).
8. Mahoney, D. J. & Stojdl, D. F. Molecular pathways: multimodal cancer-killing mechanisms employed by oncolytic vesiculoviruses. Clin Cancer Res 19, 758-763 (2013).
9. Bridle, B. W., Hanson, S. & Lichty, B. D. Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev 21, 143-148 (2010).
10. Naik, S. & Russell, S. J. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert opinion on biological therapy 9, 1163-1176 (2009).
11. Prestwich, R. J. et al. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 8, 1581-1588 (2008).
12. Sivendran, S., Pan, M., Kaufman, H. L. & Saenger, Y. Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert opinion on biological therapy 10, 1145-1153 (2010).
13. Melcher, A., Parato, K., Rooney, C. M. & Bell, J. C. Thunder and lightning: immunotherapy and oncolytic viruses collide. Molecular therapy: the journal of the American Society of Gene Therapy 19, 1008-1016 (2011).
14. Naik, S., Nace, R., Barber, G. N. & Russell, S. J. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer gene therapy 19, 443-450 (2012).
15. Alvarez-Breckenridge, C. A. et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 18, 1827-1834 (2012).
16. Ikeda, K. et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5, 881-887 (1999). (Pubitemid 29372413)
17. Thomas, M. A. et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Molecular therapy: the journal of the American Society of Gene Therapy 16, 1665-1673 (2008).
18. Peng, K. W. et al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther 20, 255-261 (2012).
19. Breitbach, C. J. et al. Targeting tumor vasculature with an oncolytic virus. Molecular therapy: the journal of the American Society of Gene Therapy 19, 886-894 (2011).
20. Smith, E., Breznik, J. & Lichty, B. D. Strategies to enhance viral penetration of solid tumors. Human gene therapy 22, 1053-1060 (2011).
21. Correia, A. L. & Bissell, M. J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 15, 39-49 (2012).
22. Fernandez, M., Porosnicu, M., Markovic, D. & Barber, G. N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76, 895-904 (2002). (Pubitemid 34033386)
23. Stojdl, D. F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6, 821-825 (2000). (Pubitemid 30469434)
24. van den Elsen, P. J., Holling, T. M., van der Stoep, N. & Boss, J. M. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. Clin Immunol 109, 46-52 (2003). (Pubitemid 37324741)
25. Goel, A. et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110, 2342-2350 (2007). (Pubitemid 47523154)
26. De Palma, M. & Lewis, C. E. Cancer: Macrophages limit chemotherapy. Nature 472, 303-304 (2011).
27. Lallemand, C., Lebon, P., Rizza, P., Blanchard, B. & Tovey, M. G. Constitutive expression of specific interferon isotypes in peripheral blood leukocytes from normal individuals and in promonocytic U937 cells. J Leukoc Biol 60, 137-146 (1996). (Pubitemid 26248893)
28. Ramachandran, A., Parisien, J. P. & Horvath, C. M. STAT2 is a primary target for measles virus V protein-mediated alpha/beta interferon signaling inhibition. J Virol 82, 8330-8338 (2008).
29. Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912 (2008).
30. Mantovani, A., Sica, A., Allavena, P., Garlanda, C. & Locati, M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 70, 325-330 (2009).
31. Zamarron, B. F. & Chen, W. Dual roles of immune cells and their factors incancer development and progression. Int J Biol Sci 7, 651-658 (2011).
32. Muthana, M. et al. Useofmacrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res 71, 1805-1815 (2011).
33. Schoppmann, S. F. et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161, 947-956 (2002). (Pubitemid 34988382)
34. Schoppmann, S. F. et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 139, 839-846 (2006). (Pubitemid 43902914)
35. Chen, J. J. et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23, 953-964 (2005). (Pubitemid 46202315)
36. Hanada, T. et al. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 7, 263-269 (2000). (Pubitemid 30440592)
37. Lin, C. W., Shen, S. C., Ko, C. H., Lin, H. Y. & Chen, Y. C. Reciprocal activation of macrophages and breast carcinoma cells by nitric oxide and colony-stimulating factor-1. Carcinogenesis 31, 2039-2048 (2010).
38. DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1, 54-67 (2011).
39. Bose, S. & Banerjee, A. K. Innate immune response against nonsegmented negative strand RNA viruses. J Interferon Cytokine Res 23, 401-412 (2003). (Pubitemid 37034578)
40. Basu, M. et al. Inhibition of vesicular stomatitis virus infection in epithelial cells by alpha interferon-induced soluble secreted proteins. J Gen Virol 87, 2653-2662 (2006).
41. Moerdyk-Schauwecker, M. et al. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 436, 221-234 (2013).
42. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu Rev Biochem 67, 227-264 (1998). (Pubitemid 28411130)
43. Sadler, A. J. & Williams, B. R. Interferon-inducible antiviral effectors. Nat Rev Immunol 8, 559-568 (2008). (Pubitemid 351913674)
44. Proietti, E., Gessani, S., Belardelli, F. & Gresser, I. Mouse peritoneal cells confer an antiviral state on mouse cell monolayers: role of interferon. J Virol 57, 456-463 (1986). (Pubitemid 16147848)
45. Hastie, E. & Grdzelishvili, V. Z. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol 93, 2529-2545 (2012).
46. Barber, G. N. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 17, 516-527 (2004). (Pubitemid 40054231)
47. Lichty, B. D., Power, A. T., Stojdl, D. F. & Bell, J. C. Vesicular stomatitis virus: reinventing the bullet. Trends Mol Med 10, 210-216 (2004). (Pubitemid 38581793)
48. Ahmed, M., Cramer, S. D. & Lyles, D. S. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330, 34-49 (2004). (Pubitemid 39446565)
49. Paglino, J. C. & van den Pol, A. N. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol 85, 9346-9358 (2011).
50. Saloura, V. et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Human gene therapy 21, 51-64 (2010).
51. Constantinescu, S. N., Girardot, M. & Pecquet, C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 33, 122-131 (2008).
52. Sansone, P. & Bromberg, J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30, 1005-1014 (2012).